company background image
ADAP logo

Adaptimmune Therapeutics NasdaqGS:ADAP Rapporto sulle azioni

Ultimo prezzo

US$0.80

Cap. di mercato

US$204.5m

7D

8.5%

1Y

36.2%

Aggiornato

04 Nov, 2024

Dati

Dati finanziari dell'azienda +

Adaptimmune Therapeutics plc

NasdaqGS:ADAP Rapporto sulle azioni

Cap. di mercato: US$204.5m

Adaptimmune Therapeutics plc Concorrenti

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Adaptimmune Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.80
Massimo di 52 settimaneUS$2.05
Minimo di 52 settimaneUS$0.42
Beta2.19
1Variazione di 1 mese-15.90%
Variazione a 3 mesi-20.02%
Variazione di 1 anno36.21%
3Variazione a 3 anni-85.92%
Variazione a 5 anni-2.17%
Variazione dall'IPO-95.36%

Notizie e aggiornamenti recenti

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Recent updates

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 03

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10
Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

Circling Back On Adaptimmune Therapeutics

Dec 15

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Sep 29

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches

Jul 29

Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts

Jun 16

Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow

Jun 05

Rendimenti per gli azionisti

ADAPUS BiotechsUS Mercato
7D8.5%-0.7%-1.6%
1Y36.2%19.8%30.8%

Ritorno vs Industria: ADAP exceeded the US Biotechs industry which returned 19.8% over the past year.

Rendimento vs Mercato: ADAP exceeded the US Market which returned 30.8% over the past year.

Volatilità dei prezzi

Is ADAP's price volatile compared to industry and market?
ADAP volatility
ADAP Average Weekly Movement10.1%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Prezzo delle azioni stabile: ADAP's share price has been volatile over the past 3 months compared to the US market.

Volatilità nel tempo: ADAP's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
2008449Ad Rawcliffewww.adaptimmune.com

Adaptimmune Therapeutics plc, azienda biofarmaceutica in fase clinica, fornisce nuove terapie cellulari principalmente a pazienti oncologici negli Stati Uniti e nel Regno Unito. L'azienda sviluppa SPEARHEAD-1, che è in fase II di sperimentazione clinica con ADP-A2M4 per il sarcoma sinoviale; SURPASS-3, che è in fase II di sperimentazione clinica con ADP-A2M4CD8 per i pazienti affetti da carcinoma ovarico resistente al platino; e SURPASS, che è in fase I di sperimentazione clinica in pazienti affetti da tumori della testa e del collo e uroteliali. L'azienda ha un accordo di collaborazione strategica e di licenza con Genentech, Inc. e F. Hoffman-La Roche Ltd per lo sviluppo di terapie personalizzate a base di cellule T allogeniche e allogeniche; un accordo di ricerca, collaborazione e licenza con Universal Cells, Inc.; collaborazioni di terze parti con Noile-Immune e Alpine Immune Sciences; e un accordo di alleanza strategica con il MD Anderson Cancer Center.

Adaptimmune Therapeutics plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Adaptimmune Therapeutics con la sua capitalizzazione di mercato?
ADAP statistiche fondamentali
Capitalizzazione di mercatoUS$204.55m
Guadagni(TTM)-US$72.50m
Ricavi(TTM)US$141.46m

1.4x

Rapporto P/S

-2.8x

Rapporto P/E

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ADAP Conto economico (TTM)
RicaviUS$141.46m
Costo del fatturatoUS$146.65m
Profitto lordo-US$5.19m
Altre speseUS$67.31m
Guadagni-US$72.50m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 13, 2024

Utile per azione (EPS)-0.28
Margine lordo-3.67%
Margine di profitto netto-51.25%
Rapporto debito/patrimonio netto25.9%

Come si è comportato ADAP nel lungo periodo?

Vedi performance storica e confronto